Results
|
|
1.
|
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. MedStar authors:
Year: 2023
Citation: - Breast Cancer Research & Treatment. 199(2):243-252, 2023 Jun.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
- Journal Article
- Randomized Controlled Trial
All authors: - Azar CA, Baez-Diaz L, Bandos H, Bear HD, Boileau JF, Brufsky AM, Geyer CE Jr Hassan S, Magrinat GC, Mamounas EP, Paik S, Rastogi P, Sarwar S, Shibata HR, Suga JM, Swain SM, Tang G, Wolmark N, Yothers G
|
|
|
2.
|
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naive chronic lymphocytic leukemia: a phase 2 study. MedStar authors:
Year: 2021
Citation: - Leukemia & Lymphoma. 62(8):1816-1827, 2021 08.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ahn IE, Desai S, Drinkwater DC, Farooqui MZ, Gaglione EM, Herman SEM, Hughes TE, Lindorfer MA, Lotter J, Maric I, Marti GE, Mo C, Nichols C, Nierman P, Pleyer C, Soto S, Stetler-Stevenson M, Sun C, Superata J, Taylor RP, Tian X, Valdez J, Wake L, Wiestner A, Yuan CM
|
|
|
3.
|
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors:
Year: 2013
Citation: - Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM
|
|
|
4.
|
|
|
|
5.
|
Avastin withdrawal symptoms. MedStar authors:
- Lynce, Filipa
- Swain, Sandra M
Citation: - Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb.
Institution: - Washington Cancer Institute
Medline publication type:
- Editorial
- Research Support, Non-U.S. Gov't
|
|
|
6.
|
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors:
Year: 2013
Citation: - Annals of Oncology. 24(10):2630-5, 2013 Oct.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM
|
|
|
7.
|
|
|
|
8.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(6):461-71, 2013 May.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
|
9.
|
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. MedStar authors:
Citation: - Lancet Oncology. 16(8):957-66, 2015 Aug.
Institution: - MedStar Washington Hospital Center
Department: - Surgery/Colorectal Surgery
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, N.I.H., Extramural
All authors: - Avila K, Cataldo PA, Chow OS, Coutsoftides T, Dietz DW, Fichera A, Garcia-Aguilar J, Herzig DO, Hunt SR, Kumar AS, Marcet JE, Oommen S, Patil S, Polite BN, Smith DD, Stamos MJ, Ternent CA, Timing of Rectal Cancer Response to Chemoradiation Consortium, Varma MG
|
|
|
10.
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors:
Year: 2012
Citation: - New England Journal of Medicine. 366(4):310-20, 2012 Jan 26.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
All authors: - Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
|
|
|
11.
|
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(12):1600-1609, 2017 Dec
Institution: - MedStar Franklin Square Hospital
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Deitz AC, Fulop A, Gottfried M, Hotta K, Hui R, Lubiniecki GM, O'Brien M, Peled N, Rangwala R, Rao S, Reck M, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhang J
|
|
|
12.
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(12):1183-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N
|
